| Symbol | VNRX |
|---|---|
| Name | VOLITIONRX LTD |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Address | 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV 89014 |
| Telephone | 1 (512) 774-8930 |
| Fax | — |
| — | |
| Website | https://www.volition.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000093314 |
| Description | VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. Additional info from NASDAQ: |
New Form S-8 - VOLITIONRX LTD <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001477932-26-005229 <b>Size:</b> 312 KB
Read moreVolition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Read moreNew Form EFFECT - VOLITIONRX LTD <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 9999999995-26-002355 <b>Size:</b> 1 KB
Read moreVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
Read moreNew Form 424B5 - VOLITIONRX LTD <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001477932-26-003713 <b>Size:</b> 416 KB
Read moreNew Form 424B5 - VOLITIONRX LTD <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001477932-26-003669 <b>Size:</b> 430 KB
Read more